Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Tavolimab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Squamous cell cancer
- Focus Pharmacodynamics
- 27 Dec 2017 Planned number of patients changed from 70 to 35.
- 27 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 14 Nov 2017 New trial record